Acceptability, Under Use in Real Conditions Of Two Vaginal Moistures Indicated for Women With Vaginal Drying
NCT ID: NCT04342559
Last Updated: 2020-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
74 participants
INTERVENTIONAL
2020-04-06
2020-04-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The research will be carried out with two new products for use in the internal intimate region in up to 74 research participants (up to 37 participants per product - each group of 37 will use one of the products), which meet the required inclusion and exclusion criteria. At the end of the treatment, the analysis must contain a minimum number of 30 participants per product. Participants will use the test products for 22 (+ 2) days and will be evaluated and monitored throughout the study by a gynecologist to verify the effectiveness of the products and possible adverse events. In addition, a profile questionnaire will be applied at the beginning of the study (T0 - day 1) and at the end of the study, the perceived efficacy questionnaire (T22), to assess signs and symptoms of the efficacy and safety of the product used.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Gynecological Acceptability of a Health Care Product
NCT04247022
Dermal and Gynecological Acceptability (Irritability and Sensitization in the Genital Mucosa) of an Investigational Product and Evaluation of Moisture Efficacy by TEWL and Perceived Efficacy.
NCT03007615
Evaluation of Gynecological Acceptability of 3 Health Care Products
NCT04327947
Clinical Study for Perceived Effectiveness Evaluation of Moisturizing Action of Intimate Use Product in Postmenopausal Women
NCT02434887
Performance and Safety of Class IIb MD Celegyn® in VVA
NCT03823560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Vaginal moisturizers rehydrate the mucosal tissue and are absorbed by the skin, adhering to the vaginal lining, thus mimicking natural vaginal secretions. The use of vaginal moisturizers is intended to allow dryness / atrophy, vaginitis / non-hormonal vaginal atrophy and is regularly harmful or once every 2-3 days. The frequency of use is directly proportional to the severity of the atrophy (for example, the more severe the atrophy, the more frequent the application is), the effects of the moisturizer are more prolonged and the effects of the lubricant, lasting 2 to 3 days.
MOD\_PRO\_CEP Rev. 03 All-SE-UG-EP-pH-FL-062603-07 / 08-04-18-PRV01 Vaginal moisturizers use this longer to change the content of the endothelium fluid, capture the vaginal pH and thus maintain vaginal hydration and acidity. Therefore, they are particularly beneficial, not only for women with VVA / GSM symptoms that cause pain during intercourse, but also for women who are not currently sexually active, but experience discomfort on a daily basis. Since vaginal moisturizers are used to moisturize the mucosa, most contain water. For the water to stick to the mucosa, it also contains vegetable or synthetic polymers. In addition, they can use a wide variety of other excipients to provide adequate viscosity, to buffer or pH and for conservation; these additional ingredients (some synthetic polymers) affect the pH and osmolality of the moisturizer.
The products to be tested in this study are two vaginal moisturizers. These are two new products from the sponsor.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
Belamy with sinodor Vaginal Moisturizer with Odor Neutralizer - code: 062603-07
Participants will be instructed on how to use it as follows:
Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.
A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep.
Belamy (vaginal moisturizer)
The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.
Interdiction and Restriction
* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;
* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;
* Do not change genital / vaginal hygiene habits;
* Not having sexual intercourse in the 48 hours (2 days) before the research visits;
* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;
* Do not perform gynecological / intimate showers during the study period
Group II
Belamy without sinodor Vaginal Moisturizer without Odor Neutralizer - code: 062603-08
Participants will be instructed on how to use it as follows:
Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.
A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep.
Belamy (vaginal moisturizer)
The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.
Interdiction and Restriction
* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;
* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;
* Do not change genital / vaginal hygiene habits;
* Not having sexual intercourse in the 48 hours (2 days) before the research visits;
* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;
* Do not perform gynecological / intimate showers during the study period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belamy (vaginal moisturizer)
The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.
Interdiction and Restriction
* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;
* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;
* Do not change genital / vaginal hygiene habits;
* Not having sexual intercourse in the 48 hours (2 days) before the research visits;
* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;
* Do not perform gynecological / intimate showers during the study period
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Skin and intact mucosa in the test region;
* Agreement to adhere to the study's procedures and requirements and to attend the institute on the day (s) and time (s) determined for the assessments;
* Ability to consent to their participation in the study;
* Female research participants;
* Menopausal participants of any age;
* Participants who complain of vaginal dryness, classified at least as mild, and who present at least one of the following symptoms, in addition to vaginal dryness, also classified at least as mild (pain during or shortly after intercourse or discomfort during or soon after sexual intercourse).
Exclusion Criteria
* Vaginal pathology in the product application area;
* Have had sex less than 48 hours before the visit;
* Have been diagnosed with urogenital or vaginal infection in the last 30 days;
* Have used topical or systemic antibiotics, antifungals, hormone-based creams or treatment for vaginal atrophy in the last six weeks;
* Immune failure;
* Current use of the following medications for topical or systemic use: corticosteroids, immunosuppressants and antihistamines and in the last 7 days;
* History of reaction to the category of the product tested;
* Present vaginal bleeding on the day of visits;
* Other diseases or medications that may directly interfere with the study result or endanger the health of the research participant, at the discretion of the investigator.
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Libbs Farmacêutica LTDA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Augusto Theodoro de Figueiredo
São Paulo, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AllSEUGEPpHFL06260307080418
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.